Blog Tag: acquisition
On January 27, 2014, according to a press release, LifeCell Corporation acquired adipose Tissue Injector (aTI) technology for improved fat grafting procedures from the TauTona Group, a medical device incubator based in Menlo Park, California. The press release notes that LifeCell is a sister company of Kinetic Concepts, Inc. (KCI)
The press release also states that aTI is a single-use tool utilized in fat grafting procedures. aTI allows for the controlled delivery of fat, by allowing management of the pressure and flow rates during injection. According to the press release, the controlled rate can minimize damage of the injected fat and reduce the complexity of performing injections.
Furthermore, the press release notes that LifeCell’s fat grafting device, REVOLVE™ Fat Processing System, can “facilitate more efficient processing, filtering, and transferring of a patient’s own fat tissue. It enables high-volume fat processing (up to 800ml lipoaspirate) in less than 15 minutes, offering the potential to reduce operating room procedure time.” According to the press release, the Senior Vice President of LifeCell, Philip Croxford, states that LifeCell believes “the [aTI], in addition to LifeCell’s existing REVOLVE™ Fat Processing System, will offer clinicians valuable solutions from fat grafting processing through reinjection.”
President and CEO of KCI, Joe Woody, describes the effects of the purchase saying:
“With this acquisition, we will leverage the LifeCell sales channel in the reconstructive and plastic surgery fields to commercialize this exciting new technology, . . . We continue to be focused on innovation and acquisitions of technologies and platforms that both complement and further diversify our combined product portfolio.”
Valeant Pharmaceuticals announced today that it has entered into an agreement to acquire Solta Medical, a developer of energy-based medical devices for aesthetic applications. The transaction will take the form of an all-cash buyout of the outstanding shares of Solta common stock, at a price of $2.92 per share, for a total estimated value of $250 million. The transaction is expected to close during the first quarter of 2014.
Solta Medical manufactures devices such as Fraxel, Thermage CPT, Liposonix, and Claro for aesthetic applications including skin resurfacing, skin tightening, body contouring, and acne treatment. Valeant is an international pharmaceutical company with a wide range of product offerings, including prescription dermatology products. According to its press release, Valeant states that, when combined with its existing product portfolio, the acquisition of Solta’s branded devices will create the “broadest aesthetic portfolio in the industry.”
This announcement follows on the heels of Valeant’s $8.7 billion all-cash acquisition of the eye health giant, Bausch + Lomb (estimated 2013 net revenue of $3.5 billion). That transaction, which Valeant announced on May 27, 2013, closed on August 5, 2013.
On August 19, St. Jude Medical, Inc. announced the acquisition of Endosense SA. The press release notes that St. Jude Medical has made an initial payment of approximately $170 million with additional cash payments of up to $161 million contingent on achievement and timing of regulatory milestones.
According to the press release, Endosense SA, a Switzerland-based company, “has pioneered contact-force measurement in catheter ablation.” The press release notes that Endosense’s TactiCath irrigated ablation catheter provides physicians a real-time, objective measure of the force applied to the heart wall during a catheter ablation procedure.
Frank J. Callaghan, president of the Cardiovascular and Ablation Technologies Division of St. Jude Medical stated:
This transaction significantly accelerates our timeline to providing an irrigated ablation catheter that incorporates force sensing in both international and U.S. markets, and has potential future applications across other St. Jude Medical technology platforms as well.
The press release states that St. Jude Medical can incorporate the force sensing technology for use with their technologies including offering a “MediGuide-enabled force-sensing ablation catheter and to incorporate force sensing data into the company’s EnSite Velocity™ Mapping System.”
Angiotech announced this morning that it has entered into an agreement to sell its Interventional Products business line for $362.5 million in cash to Argon Medical Devices, Inc. According to the press release, the sale is expected to close before the end of April.
Angiotech describes itself as being a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. The company focuses on the areas of interventional oncology, wound closure and ophthalmology.
Argon Medical describes itself as being a global manufacturer of specialty medical products offering a broad line of medical devices for interventional radiology, vascular surgery, interventional cardiology, and critical care procedures.
According to the press release, the businesses being acquired by Argon include:
Angiotech’s BioPince™ full core biopsy devices, Tru-Core™ II (fully automatic) and SuperCore™ (semi-automatic) disposable biopsy instruments, T-Lok™ bone marrow biopsy devices, and Skater™ drainage catheters, among other products.
Angiotech will retain both its Surgical Products Business and its Royalty Business, which it describes in the press release as including intellectual property relating to the drug paclitaxel for application in drug-eluting stents that is licensed to Boston Scientific and Cook Medical.